by admin | Jun 1, 2021
Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody, which binds to free IgE, lowers free IgE levels, and causes FcεRI receptors on basophils and mast cells to be downregu-lated. Omalizumab is the first drug approved as an add-on therapy for...
by mm-red | Jul 30, 2020
Background: Recommendations in current guidelines for the treatment of chronic spontaneous urticaria (CSU) in infants and children are mostly based on extrapolation of data obtained in adults. This study reports the efficacy and safety of rupatadine, amodern H1and PAF...
Recent Comments